PFE Jan 2025 37.500 call
| Previous close | 0.1600 |
| Open | 0.1900 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 37.50 |
| Expiry date | 2025-01-17 |
| Day's range | 0.1600 - 0.1900 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Reuters
UPDATE 3-GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.
ReutersGlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
(Reuters) -GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.
- Reuters
UPDATE 1-Ad group WPP reports 1.6% drop in first-quarter organic growth
British ad group WPP reported a 1.6% drop in organic growth in the first quarter, lagging its major rivals, after it was hit by loss of business from healthcare client Pfizer and reduced spending by technology companies. WPP, which had already warned that any organic growth this year would be weighted towards the second half, on Thursday reiterated its guidance for flat to 1% growth this year, with a margin improvement of 20-40 basis points.
